Emergence of Multiclass Drug–Resistance in HIV‐2 in Antiretroviral‐Treated Individuals in Senegal: Implications for HIV‐2 Treatment in Resouce‐Limited West Africa

Abstract excerpt

BACKGROUND: The efficacy of various antiretroviral (ARV) therapy regimens for human immunodeficiency virus type 2 (HIV-2) infection remains unclear. HIV-2 is intrinsically resistant to the nonnucleoside reverse-transcriptase inhibitors and to enfuvirtide and may also be less susceptible than HIV-1 to some protease inhibitors (PIs). However, the mutations in HIV-2 that confer ARV resistance are not well...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HIV/AIDS drug development and treatment
• Share to HIV/AIDS Research and Interventions
• Share to HIV Research and Treatment